Biotech · Private company
Hemab ApS
Track this companyFree. Adds Hemab ApS to your Dealase workspace and tells you when its record changes.
Clinical trials44 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- HMB-001Phase 2 · Glanzmann ThrombastheniaClinicalTrials.gov · fetched Nov 12, 2026
- HMB-002 (Part A)Phase 2 · Von Willebrand Disease (VWD)ClinicalTrials.gov · fetched Nov 12, 2026
- HMB-002 (Part B)Phase 2 · Von Willebrand Disease (VWD)ClinicalTrials.gov · fetched Nov 12, 2026
- HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)Phase 2 · Von Willebrand Disease (VWD)ClinicalTrials.gov · fetched Nov 12, 2026
- HMB-003Phase 1 · Healthy Adult ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- Clinical outcomes of patients with VWD, Type 1Von Willebrand Disease (VWD)ClinicalTrials.gov · fetched Nov 12, 2026
- Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3Von Willebrand Disease (VWD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy VolunteersPHASE1 · RECRUITING · started Aug 17, 2026ClinicalTrials.gov NCT07798505 · fetched Nov 12, 2026
- A Study Assessing HMB-002 in Participants With Von Willebrand DiseasePHASE1_PHASE2 · RECRUITING · started Feb 6, 2025ClinicalTrials.gov NCT06754852 · fetched Nov 12, 2026
- A Study of Bleeding and Treatment in Participants With Von Willebrand DiseaseRECRUITING · started Aug 30, 2024ClinicalTrials.gov NCT06610201 · fetched Nov 12, 2026
- A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann ThrombastheniaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 13, 2022ClinicalTrials.gov NCT06211634 · fetched Nov 12, 2026